Translation-X

Executive Summary

Translation-X is a Swiss biotech founded in 2021, pioneering novel therapeutics that target RNA translation to treat genetic diseases, with an initial focus on Autism Spectrum Disorders (ASD). Operating at the intersection of RNA and gene therapy, the company leverages a unique approach to modulate protein synthesis, potentially addressing underlying causes of ASD. As a private, early-stage company with no disclosed funding or valuation, Translation-X faces significant development and regulatory risks. However, its Basel location and innovative platform position it within a thriving biotech hub. The company's success hinges on preclinical validation and securing partnerships or funding to advance its pipeline.

Upcoming Catalysts (preview)

• Q3 2026Preclinical proof-of-concept data25% success
• Q4 2026Series A financing round30% success
• Q1 2027Collaboration or licensing deal20% success